INCY Incyte
- 63.560
- +0.200+0.32%
- 64.320
- +0.760+1.20%
Incyte News
Unusual Options Activity: F, INCY and Others Attract Market Bets, F V/OI Ratio Reaches 416.7
BofA Securities Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $66
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Cantor Fitzgerald Reiterates Neutral on Incyte
Incyte Analyst Ratings
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
Incyte To Present At Morgan Stanley Global Healthcare Conference; Webcast At 10:45 AM ET
Eli Lilly Inks Licensing Deal to Expand Olumiant Access in Africa
Express News | Eli Lilly And EVA Pharma Entered Into An Agreement To Expand Access To Baricitinib To An Estimated 20,000 People In 49 Low- To Middle-income Countries In Africa By 2030
RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $67
Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
Incyte's (NASDAQ:INCY) Earnings Have Declined Over Five Years, Contributing to Shareholders 20% Loss
The Most Concentrated Hedge Fund Positions Year-to-date - Goldman
Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024
Incyte Stock: Is Wall Street Bullish or Bearish?
Stocks With Three Weeks of Deteriorating Technicals by Piper Sandler
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
Incyte Corporation: Market Successes Counterbalanced by Valuation and Patent Expiry Concerns
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cochlear Limited (OtherCHEOF)
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
Analysis
Price Target
No Data
No Data
